About: http://data.cimple.eu/news-article/ceebb4c536992790e2543a5c73a8979cae19efd48a25b1f7b27b61f0

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/ceebb4c536992790e2543a5c73a8979cae19efd48a25b1f7b27b61f0 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The experimental antiviral drug remdesivir has failed in its first randomized clinical trial to treat the COVID-19 illness, reports said Thursday, quoting draft documents that were accidentally published by the World Health Organization. Gilead Sciences, the company behind the medicine, disputed how the now deleted post had characterized the findings, saying the data showed a "potential benefit." The Financial Times reported that researchers in China carried out a study on 237 patients, giving the drug to 158 and comparing their progress with a control group of 79. A summary of the experiment said remdesivir was "not associated with a difference in time to clinical improvement" compared to the control, according to health news site Stat, which posted a screenshot. After a month, 13.9 percent of the patients on remdesivir had died compared to 12.8 percent of those in the control group. A spokesman for Gilead told AFP: "We believe the post included inappropriate characterizations of the study," saying it was terminated early due to low enrollment and was therefore not statistically meaningful. "As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease," he said. The study does not represent the final word on the matter and there are several large-scale trials in advanced stages that should soon provide a clearer picture. Remdesivir, which is administered intravenously, was among the first drugs mooted as a treatment for the novel coronavirus and as such has great hopes riding on it. Last week, Stat reported it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated. The US National Institutes for Health also reported it had proven effective in a small experiment on monkeys. Remdesivir belongs to a class of drugs that act on the virus directly -- as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA and gets absorbed into the virus's genome, which in turn stops the pathogen from replicating. ia/acb
schema:headline	Experimental virus drug remdesivir failed in human trial: reports
schema:mentions	RNA virus Liga ACB University of Chicago Financial Times Pathogenic bacteria Autoimmunity Intravenous therapy Conscription in the United States Agence France-Presse USA Gymnastics Antiviral drug Remdesivir Medication Ia (cuneiform) World Health Organization DNA Virus China Severe acute respiratory syndrome coronavirus 2 Treatment and control groups Randomized controlled trial Gilead Sciences
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-04-23 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	82 (xsd:integer)
http://data.cimple...tology#hasEmotion	fear

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software